<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00779805</url>
  </required_header>
  <id_info>
    <org_study_id>016/ PSEUD-120/ 04</org_study_id>
    <nct_id>NCT00779805</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Pseudoephedrine HCl 120 mg ER Tablets Under Fed Conditions</brief_title>
  <official_title>An Open Label, Balanced, Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study on Pseudoephedrine Hydrochloride Formulations Comparing Pseudoephedrine Hydrochloride 120 mg ER Tablets of Ranbaxy Laboratories With Sudafed 120 mg ER Tablets of Pfizer Consumer Health Care in Healthy, Adult, Human Subjects Under Fed Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ranbaxy Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ranbaxy Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study was to compare the single dose oral bioavailability of
      Pseudoephedrine hydrochloride 120 mg ER tablets of Ranbaxy with Sudafed 120 mg ER tablets of
      Pfizer Consumer Health Care in healthy, adult, human subjects under fed conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was an open label, balanced, randomized, two-treatment, two-period, two-sequence,
      single dose crossover bioavailability study planned on 40 healthy, adult, human subjects
      under fed conditions.

      A total of forty (40) healthy, adult, human subjects were admitted in the study to allow the
      dosing in the first period. Out of the forty subjects, only thirty eight (38) subjects
      completed both the periods of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pseudoephedrine hydrochloride 120 mg ER tablets of Ranbaxy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sudafed 120 mg ER tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pseudoephedrine hydrochloride 120 mg ER tablets</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be in the age range of 18 - 45 years

          -  Be neither over weight nor under weight for his/ her height as per the Life Insurance
             Corporation of India height/ weight chart for non-medical cases

          -  Have voluntarily given written informed consent to participate in this study

          -  Be of normal health as determined by medical history and physical examination of the
             subjects performed within 14 days prior to the commencement of the study

          -  If female and:

          -  Of child bearing potential is practicing an acceptable method of birth control for the
             duration of the study as judged by the investigator (s), such as condoms, foams,
             jellies, diaphragm, intrauterine device (IUD), or abstinence; or

          -  Is postmenopausal for at least 1 year; or

          -  Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
             hysterectomy)

        Exclusion Criteria:

          -  History of allergy to Pseudoephedrine or other sympathomimetic drugs

          -  History of intake of any sympathomimetic drugs and glucocorticoids during a period of
             15 days prior to day 1 of this study.

          -  Concurrent use of monoamine oxidase inhibitor (MAOI) drugs within 14 days prior to day
             1 of this study

          -  Any evidence of organ dysfunction or any clinically significant deviations from the
             normal, in physical or clinical determinations

          -  Presence of disease markers of HIV 1 or 2, hepatitis B or C viruses or syphilis
             infection

          -  Female volunteers demonstrating a positive pregnancy test

          -  Female volunteers who are currently breastfeeding

          -  Presence of values which are significantly different from normal reference ranges (as
             defined in appendix 5) and/ or judged clinically significant for serum creatinine,
             blood urea nitrogen, serum aspartate aminotransferase (AST), serum alanine
             aminotransferase (ALT), serum alkaline phosphatase, serum bilirubin, plasma glucose or
             serum cholesterol

          -  Clinically abnormal chemical and microscopic examination of urine defined as presence
             of RBC, WBC (&gt;4/ HPF), glucose (positive) or protein (positive)

          -  Clinically abnormal ECH or chest X-ray

          -  History of serious gastrointestinal, hepatic, renal, pulmonary, neurological or
             hematological diseases or glaucoma

          -  History of cardiovascular disorders (including hypertension), endocrine disorders,
             hyperthyroidism, diabetes mellitus, prostatic hypertrophy, palpitations, insomnia,
             tremors or bronchial asthma

          -  History of any psychiatric illness which may impair the ability to provide written
             informed consent

          -  Regular smokers who smoke more than 10 cigarettes daily or have difficulty abstaining
             from smoking for the duration of each study period.

          -  History of drug dependence or excessive alcohol intake on a habitual basis of more
             than 2 units of alcoholic beverages per day (1 unit equivalent to half pint of beer or
             1 glass of wine or 1 measure of spirit) or have difficulty in abstaining for the
             duration of each study period

          -  Use of any enzyme modifying drugs within 30 days prior to day 1 of this study

          -  Participation in any clinical trail within 12 weeks preceding day 1 of this study

          -  Subjects who, through completion of this study, would have donated and / or lost more
             than 350 mL of blood in the past 3 months.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ranbaxy CPU</name>
      <address>
        <city>Gurgaon</city>
        <state>Haryana</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.ranbaxy.com</url>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/Enforce.html</url>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
  </link>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2008</study_first_submitted>
  <study_first_submitted_qc>October 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2008</study_first_posted>
  <last_update_submitted>October 23, 2008</last_update_submitted>
  <last_update_submitted_qc>October 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Tausif Monif</name_title>
    <organization>Ranbaxy Research Labs</organization>
  </responsible_party>
  <keyword>Bioequivalence Pseudoephedrine hydrochloride 120 mg ER tablets</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

